Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7270749 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHR | |
| SCHEMBL5907764 | 0.83 | ALDH1A1 (0.33) | ALDH1A1TSHR | |
| SCHEMBL26915243 | 0.78 | ALDH1A1 (0.35) | ALDH1A1TSHR | |
| SCHEMBL16928460 | 0.73 | TSHR (0.31) | ALDH1A1TSHR | |
| SCHEMBL6347557 | 0.71 | — | — | |
| SCHEMBL7410494 | 0.71 | — | — | |
| SCHEMBL5907754 | 0.70 | — | — | |
| SCHEMBL30656396 | 0.70 | — | — | |
| SCHEMBL18584687 | 0.70 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL1061431 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2176208-B1 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS INC (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8293786-B2 | Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same | ALLTRANZ INC. (US) | 2012-10-23 | — | — | US | disclosed |
| EP-2176208-A1 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | AllTranz Inc. (US) | 2010-04-21 | — | — | EP | disclosed |
| US-20090036523-A1 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | ALLTRANZ INC. (US) | 2009-02-05 | — | — | US | disclosed |
| WO-2009018389-A1 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | ALLTRANZ INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20060149090-A1 | Process for producing chain oligolactic acid ester | AMATO PHARMACEUTICAL PRODUCTS, LTD. (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1484311-A1 | PROCESS FOR PRODUCING CHAIN OLIGOLACTIC ACID ESTER | AMATO PHARMACEUTICAL PRODUCTS, LTD. (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-5912238-A | REVERSING DRUG RESISTANCE WITH MACROLIDE COMPOUNDS | NOVARTIS AG (CH) | 1999-06-15 | — | — | US | disclosed |
| EP-0427680-B1 | Heteroatoms-containing tricyclic compounds | SANDOZ LTD (CH) | 1995-08-23 | — | — | EP | disclosed |
| US-5352671-A | Heteroatoms-containing tricyclic compounds | SANDOZ LTD. (CH) | 1994-10-04 | — | — | US | disclosed |
| EP-0427680-A1 | Heteroatoms-containing tricyclic compounds | SANDOZ LTD. (CH) | 1991-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036523-A1 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | ALDH1A1 1490/4885TSHR 3837/4885 |
| US-20060149090-A1 | Process for producing chain oligolactic acid ester | ELOVL1, OSTC, ACSL1 | ALDH1A1 403/4885TSHR 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.